

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/550,313
				Filing Date	September 22, 2005
				First Named Inventor	Eldridge et al.
				Art Unit	unassigned
				Examiner Name	unassigned
Sheet	4	of	5	Attorney Docket Number	AM-101319

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AAX	MCSHANE et al., "Enhanced Immunogenicity of CD4 <sup>+</sup> T-Cell Responses and Protective Efficacy of DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis", Infect. Immun., 69(2): 681-686 (February, 2001)	
	AAY	DEGANO et al., "Gene Gun Intradermal DNA Immunization Followed by Boosting with Modified Vaccinia Virus Ankara: Enhanced CD8 <sup>+</sup> T Cell Immunogenicity and Protective Efficacy in the Influenza and Malaria Models", Vaccine, 18(7-8):623-632 (November 12, 1999)	
	AAZ	MENG et al., "α-Fetoprotein-Specific Tumor Immunity Induced by Plasmid Prime-Adenovirus Boost Genetic Vaccination", Cancer Res., 61:8782-8786 (December 15, 2001)	
	BR	HAMMOND et al., "A Prime-Boost Vaccination Strategy Using Naked DNA Followed by Recombinant Porcine Adenovirus Protects Pigs from Classical Swine Fever", Vet. Microbiol., 80(2):101-109 (May 21, 2001)	
	BS	MATANO et al., "Rapid Appearance of Secondary Immune Responses and Protection from Acute CD4 Depletion after a Highly Pathogenic Immunodeficiency Virus Challenge in Macaques Vaccinated with a DNA Prime/Sendai Virus Vector Boost Regimen", J. Virol., 75(23): 11891-11896 (December, 2001)	
	BT	KENT et al., "Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus", J. Virol., 72(12): 10180-10188 (December, 1998)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/550,313
				Filing Date	September 22, 2005
				First Named Inventor	Eldridge et al.
				Art Unit	unassigned
				Examiner Name	unassigned
Sheet	5	of	5	Attorney Docket Number	AM-101319

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>	
	BU	ROBINSON et al., "Neutralizing Antibody-Independent Containment of Immunodeficiency Virus Challenges by DNA Priming and Recombinant Pox Virus Booster Immunizations", Nat. Med., 5(5): 526-534 (May, 1999)		
	BV	TARTAGLIA et al., "Canarypox Virus-Based Vaccines: Prime-Boost Strategies to Induce Cell-Mediated and Humoral Immunity Against HIV", AIDS Res. Hum. Retroviruses, 14(S3):S291-298 (October, 1998)		
	BW	SUTTER et al., "Novel Vaccine Delivery Systems: Solutions to HIV Vaccine Dilemmas?", AIDS, 15(S): S139-S145 (2001)		
	BX	ROSE NINA et al., "An Effective AIDS Vaccine Based on Live Attenuated Vesicular Stomatitis Virus Recombinants", Cell, 106(5): 539-549 (September 7, 2001)		
	BY	EGAN et al., "The Use of Cytokines and Chemokines as Genetic Adjuvants for Plasmid DNA Vaccines", Clin. Appl. Immunol. Rev., 2(4-5) 255-287 (2002)		
	BZ	SHIVER et al., "Replication-Incompetent Adenoviral Vaccine Vector Elicits Effective Anti-Immunodeficiency-Virus Immunity", Nature, 415:331-335 (February 17, 2002)		
	BBR	HAGLUND et al., "High-Level Primary CD8+ T-Cell Response to Human Immunodeficiency Virus Type I Gag and Env Generated by Vaccination with Recombinant Vesicular Stomatitis Viruses", J. Virol., 76(6): 2730-2738 (March, 2002)		
	BBS	ROBERTS et al., "Attenuated Vesicular Stomatitis Viruses as Vaccine Vectors", J. Virol., 73(5): 3723-3732 (May, 1999)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.